Biolegend, 135220, Brilliant Violet 605™ anti-mouse CD279 (PD-1) Antibody, 50μg

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
Application References(PubMed link indicates BioLegend citation): Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block) Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block) Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed Wrzner K, et al. 2021. EBioMedicine. 63:103197. PubMed Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed Lee JH, et al. 2022. Cell Rep. 38:110485. PubMed Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed Eschweiler S 2023. Cell Reports. 42(2):112040. PubMed Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed Verma S, et al. 2016. J Virol. 90: 650 - 658. PubMed Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed Wang D, et al. 2018. Immunity. 48:659. PubMed Stathopoulou C, et al. 2020. Immunity. 49(2):247-263.e7.. PubMed Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed Baram T, et al. 2021. Cells. 10:. PubMed Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed Lindenstrøm T et al. 2017. EBioMedicine. 27:27-39 . PubMed DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed Porsche CE, et al. 2021. JCI Insight. 6:. PubMed Rodriguez AB, et al. 2021. Cell Reports. 36(3):109422. PubMed Best SA, et al. 2018. Cell Metab. 27:935. PubMed Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed Marro BS, et al. 2019. Cell Rep. 29:3293. PubMed Levi J, et al. 2020. J Nucl Med. . PubMed Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed Xu S, et al. 2021. Immunity. . PubMed Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed Kurniawan H, et al. 2020. Cell Metabolism. 31(5):920-936. PubMed Vogel AB, et al. 2021. Nature. 592:283. PubMed Tan X, et al. 2021. Sci Adv. 7: . PubMed Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Sandu I, et al. 2020. Cell Reports. 32(8):108078. PubMed Fu Y, et al. 2021. Front Cell Dev Biol. 9:689727. PubMed Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed Wen J, et al. 2020. Cell Rep. 31:107566. PubMed Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed Schulze J, et al. 2021. Stroke. 52:2939. PubMed Gangoso E, et al. 2021. Cell. 184:2454. PubMed
RRID: AB_11125371 (BioLegend Cat. No. 135219) AB_2562616 (BioLegend Cat. No. 135220)
Structure: A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution: Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
Function: Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor: B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type: B cells, T cells
Biology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: 1. Nishimura H, et al. 2001. Science 291:319 2. Agata Y, et al. 1996. Int. Immunol. 8:765 3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706 4. Barber DL, et al. 2006. Nature 439:682 5. Keir ME, et al. 2005. J. Immunol. 175:7372 6. Koehn BH. et al. 2008. J Immunol. 181:5313
Gene ID: 18566
UniProt: View information about CD279 on UniProt.org
Clone: 29F.1A12
Regulatory Status: RUO
Other Names: PD-1, Programmed Death-1, PDCD1
Isotype: Rat IgG2a, κ